HPV Country Profile

Statistics and Data Analytics


cases in 2018



deaths in 2018

Status of National HPV Vaccination Programme

The HPV vaccine is currently not included in Algeria’s national immunization program.


General Information

Human Papillomavirus

Burden of HPV infection

In Algeria, about 2.1% of women in the general population are estimated to have HPV type 16 or 18 at a given time, which causes approximately 76.8% of invasive cervical cancers in the country. A 2012 study found that approximately 14% of Algerian women have any type of HPV.4

Burden of cervical cancer:

Cervical cancer, caused by HPV, is the sixth leading cause of cancer deaths in women in Algeria, causing at least 1066 deaths annually among the population of 14.5 million Algerian women aged 15 years and older who are at risk for the disease.1,2 Between 2012 and 2018, the number of deaths every year due to cervical cancer doubled (510 in 2012 to 1066 in 2018), and if decisive action is not taken at the national level, annual deaths due to the disease will double again by 2040, reaching 2244 deaths per year.3 In Algeria, at least 1594 women are newly diagnosed with cervical cancer each year.

8.1 per 100,000 women in Algeria contract cervical cancer annually and 5.5 per 100,000 Algerian women die due to cervical cancer each year. Among countries in the MENA region (as defined by UNAIDS), Algeria’s death and incidence rates due to cervical cancer are relatively high. For example, Somalia and Morocco have the highest incidence and mortality rates, with 24.0 and 17.2 women per 100,000 being newly diagnosed with cervical cancer annually and at least 21.9 and 12.6 women per 100,000 dying due to cervical cancer per year, respectively. Whereas Iran, Iraq and Yemen have the lowest (around 2 per 100,000 women are diagnosed per year and about 1 per 100,000 die because of cervical cancer annually).2

Cervical cancer incidence and mortality rate projections
Research and Publications
  1. Hamdi Cherif, Mokhtar, et al. “Time Trends of Cancer Incidence in Setif, Algeria, 1986–2010: An Observational Study.” BMC Cancer, vol. 14, no. 1, Aug. 2014, p. 637, doi:10.1186/1471-2407-14-637.
  2. Combes, Jean-Damien, et al. “Antibodies against High-Risk Human Papillomavirus Proteins as Markers for Invasive Cervical Cancer.” International Journal of Cancer, vol. 135, no. 10, 2014, pp. 2453–61, doi:10.1002/ijc.28888.
  3. Khenchouche, Abdelhalim, et al. “Human Papillomavirus and Epstein-Barr Virus Co-Infection in Cervical Carcinoma in Algerian Women.” Virology Journal, vol. 10, no. 1, Nov. 2013, p. 340, doi:10.1186/1743-422X-10-340.
  4. Hammouda, Doudja, et al. “Human Papillomavirus Infection in a Population-Based Sample of Women in Algiers, Algeria.” International Journal of Cancer, vol. 128, no. 9, 2011, pp. 2224–29, doi:10.1002/ijc.25539.
  5. Hammouda, Doudja, et al. “Cervical Carcinoma in Algiers, Algeria: Human Papillomavirus and Lifestyle Risk Factors.” International Journal of Cancer, vol. 113, no. 3, 2005, pp. 483–89, doi:10.1002/ijc.20600.
View all publications
  1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Algeria. Summary Report 27 July 2017. [19 October, 2018]

  2. Cancer Today. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  3. Cancer Tomorrow. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  4. Khenchouche A, Sadouki N, Boudriche A, Houali K, Graba A, Ooka T, Bouguermouh A. (2012). Human Papillomavirus and Epstein-Barr virus co-infection in Cervical Carcinoma in Algerian women. Virology Journal, 10:340. doi:10.1186/1743-422X-10-340

Please notify us if you know of other resources, including academic publications, news articles and information that should be added to this page by emailing: hpvmena@gmail.com.